Literature DB >> 18063342

P-glycoprotein-mediated efflux of phenobarbital at the blood-brain barrier evidence from transport experiments in vitro.

Zhi-Hong Yang1, Xiao-Dong Liu.   

Abstract

The purpose of the present studies was to investigate characteristics of phenobarbital (PB) transport across the blood-brain barrier (BBB). Cultured rat brain microvascular endothelial cells (rBMECs) were used as an in vitro BBB model. Experiments were conducted to examine time-, concentration- and temperature-dependent elements of PB uptake, and the effect of tested agents on the steady-state uptake of PB. PB efflux from rBMECs and the polarised transport of PB were examined to evaluate whether P-glycoprotein (P-gp) was involved in the PB efflux transport across BBB. The results demonstrated that the uptake of PB by rBMECs was in a time-, concentration- and temperature-dependent manner. P-gp modulators, cyclosporin A (CsA), ketoconazole and metabolic inhibitor dinitrophenol, increased the PB steady-state uptake by more than 50% (p < 0.01), and decreased the PB efflux by more than 50% (p < 0.01). Similar results were observed in the uptake and efflux studies of rhodamine-123 by co-administration of CsA. Further results were obtained in the polarised transendothelial transport of PB in the apical to basolateral (A-B) and basolateral to apical (B-A) directions either with or without CsA. The result showed that transport of PB in the B-A direction was significantly greater than the transport in the A-B direction (p < 0.05), and the co-administration of 50microM CsA almost inhibited P-gp-involved efflux in the rBMECs. Overall, these findings suggest that P-gp may contribute to the efflux transport of PB across BBB.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18063342     DOI: 10.1016/j.eplepsyres.2007.10.006

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  5 in total

1.  Verapamil exerts biphasic modulation on phenobarbital transport across the blood-brain barrier: evidence from an in vivo and in vitro study.

Authors:  Dan Yao; Zhi-Hong Yang; Li Liu; Jia Li; Yun-Li Yu; Lu-Lu Zhang; Xian Pan; Xiao-Dong Liu; Lin Xie; Guang-Ji Wang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-02-19       Impact factor: 3.000

2.  Bile duct ligation causes opposite impacts on the expression and function of BCRP and P-gp in rat brain partly via affecting membrane expression of ezrin/radixin/moesin proteins.

Authors:  Tong Wu; Yun Sheng; Yuan-Yuan Qin; Wei-Min Kong; Meng-Meng Jin; Han-Yu Yang; Xiao-Ke Zheng; Chang Dai; Ming Liu; Xiao-Dong Liu; Li Liu
Journal:  Acta Pharmacol Sin       Date:  2021-02-08       Impact factor: 7.169

Review 3.  Alterations in function and expression of ABC transporters at blood-brain barrier under diabetes and the clinical significances.

Authors:  Li Liu; Xiao-Dong Liu
Journal:  Front Pharmacol       Date:  2014-12-10       Impact factor: 5.810

Review 4.  A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care.

Authors:  Richard E Kast; John A Boockvar; Ansgar Brüning; Francesco Cappello; Wen-Wei Chang; Boris Cvek; Q Ping Dou; Alfonso Duenas-Gonzalez; Thomas Efferth; Daniele Focosi; Seyed H Ghaffari; Georg Karpel-Massler; Kirsi Ketola; Alireza Khoshnevisan; Daniel Keizman; Nicolas Magné; Christine Marosi; Kerrie McDonald; Miguel Muñoz; Ameya Paranjpe; Mohammad H Pourgholami; Iacopo Sardi; Avishay Sella; Kalkunte S Srivenugopal; Marco Tuccori; Weiguang Wang; Christian R Wirtz; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2013-04

5.  Altered Function and Expression of ABC Transporters at the Blood-Brain Barrier and Increased Brain Distribution of Phenobarbital in Acute Liver Failure Mice.

Authors:  Li Liu; Mingxing Miao; Yang Chen; Zhongjian Wang; Binbin Sun; Xiaodong Liu
Journal:  Front Pharmacol       Date:  2018-03-06       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.